SCNI: SCNI Q1 — Acquires Recipharm Israel to expand CDMO; revenue down, GAAP profit from bargain purchase

AI Summary

Scinai (SCNI) reported Q1 2026 results and completed the acquisition of Recipharm Israel, consolidating CDMO operations under Scinai Biopharma Services and striking a strategic commercial collaboration with Recipharm AB that adds a Yavne manufacturing site and broader biologics/sterile/small-molecule capabilities. Financials: revenue was $0.489M (vs. $0.586M year‐ago), cost of revenues rose to $1.6M and operating loss widened to $2.5M, but GAAP net income was $3.6M driven by a $6.2M non‐cash bargain purchase gain from the acquisition; cash was $3.1M at quarter end. Management is prioritizing non‐dilutive grant funding while advancing PC111 and a systemic IL‐17 bispecific NanoAb as the lead NanoAb validation program.

Positives

Completed acquisition of Recipharm Israel and commercial collaboration with Recipharm AB, adding a second CDMO site in Yavne and expanded service offerings
Acquisition added ~ $6.2M of net identifiable assets (including ~$2.8M cash and ~$3.6M equipment) and generated a ~$6.2M non‑cash bargain purchase gain that produced positive GAAP net income
Pursuing multiple non‑dilutive grants and has prioritized a systemic IL‑17 bispecific NanoAb as the lead NanoAb validation program while advancing PC111

Negatives

Q1 revenue fell to $489k from $586k year‑over‑year
Cost of revenues jumped to $1.6M and operating loss widened to $2.5M, reflecting CDMO expansion and a change in cost allocation
Cash balance is modest at $3.1M as of March 31, 2026